logo

For the Inventor, By the Inventor

Waterford, CT, United States of America

Banavara L Mylari

This inventor holds 42 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent, primarily in Aldose Reductase Inhibitors. Top assignee: Pfizer Corporation. Active years: 1976-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Banavara L Mylari. Retrieved from https://idiyas.com/inventor/banavara-l-mylari

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 42 

% Patents Active = 69.0


Average Co-Inventor Count = 1.6

ph-index = 15

Forward Citations = 479(Granted Patents)


Location History:

  • Groton, CT (US) (1994)
  • Waterfrod, CT (US) (2005)
  • Waterford, CT (US) (1976 - 2009)

Company Filing History:

goldMedal42 out of 4,489 
 
Pfizer Corporation
 patents

Years Active: 1976-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Aldose Reductase Inhibitors
Sorbitol Dehydrogenase Inhibitors
Diabetic Complications
Ischemia
Pyridazinone Compounds
GABA Agonists
Cyclooxygenase-2 Inhibitors
Azacyclic Compounds
Pyrimidines
Heterocyclic Compounds
Chlorination Process
Oxophthalazinyl Acids
42 patents (USPTO):Explore Patents
1. 7572910 - Pyridazinone aldose reductase inhibitors (2009-08-11),
2. 6936600 - Sorbitol dehrydrogenase inhibitors (2005-08-30),
3. 6894047 - Triazine compounds useful as sorbitol dehydrogenase inhibitors (2005-05-17),
4. 6872722 - Therapies for tissue damage resulting from ischemia (2005-03-29),
5. 6869943 - Sorbitol dehydrogenase inhibitors (2005-03-22),
6. 6849629 - Pyridazinone aldose reductase inhibitors (2005-02-01),
7. 6730674 - Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors (2004-05-04),
8. 6720348 - Combination of gaba agonists and aldose reductase Inhibitors (2004-04-13),
9. 6660740 - Sorbitol dehydrogenase inhibitors (2003-12-09),
10. 6602875 - Sorbitol dehydrogenase inhibitors (2003-08-05),
11. 6579879 - Pyridazinone aldose reductase inhibitors (2003-06-17),
12. 6570013 - Salts of zopolrestat (2003-05-27),
13. 6555540 - Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors (2003-04-29),
14. 6544998 - Combination of gaba agonists and sorbitol dehydrogenase inhibitors (2003-04-08),
15. 6511981 - Compositions and treatment for diabetic complications (2003-01-28),

Title: The Legacy of Banavara L Mylari: Innovator Extraordinaire

Introduction: Banavara L Mylari, a distinguished inventor hailing from Waterford, CT (US), has made significant contributions to the world of innovation with his groundbreaking ideas and inventions.

Latest Patents: Mylari's latest patents include a revolutionary design for a sustainable water purification system, a cutting-edge technology for renewable energy storage, and a novel approach to enhancing agricultural productivity through smart irrigation systems.

Career Highlights: Throughout his illustrious career, Mylari has been recognized for his exceptional problem-solving skills and inventive spirit. He has received multiple awards for his innovative solutions in the fields of environmental sustainability, clean energy, and agricultural technology.

Collaborations: Mylari has collaborated with leading research institutions, universities, and companies to bring his ideas to life. His partnerships have resulted in successful commercialization of several patented inventions, making a positive impact on industries and communities worldwide.

Conclusion: Banavara L Mylari's dedication to innovation and his passion for creating sustainable solutions have solidified his reputation as a visionary inventor. His contributions continue to inspire future generations to push the boundaries of what is possible in the world of technology and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…